Young adults with gastrointestinal and neuroendocrine cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a platform for collecting biological samples from young adults diagnosed with gastrointestinal and neuroendocrine cancers. It focuses on identifying predictive and prognostic biomarkers that can help in understanding the unique characteristics and needs of this patient population. The study includes patients aged 18 to 39 years with various types of carcinomas and neuroendocrine neoplasms, regardless of tumor stage or grade. By addressing the underrepresentation of young adults in clinical studies, the research seeks to improve knowledge about risk factors and treatment outcomes for these cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age at diagnosis from18 to 39 years of age
* Carcinoma (without limitations for histologic subtypes) from any primary sites: esophagus, stomach, pancreas, biliary tract, liver, small bowel, colon, rectum, anus and cancer of unknown origin
* Neuroendocrine neoplasm (NEN) from Gastroenteropancreatic GEP or lung/thymus origin
* Tumors at any stage at the first visit
* Tumors of any grade
* Histological diagnosis obtained within two years from the time of enrollment or willingness to undergo bioptic procedure for diagnosis

Exclusion Criteria:

* Age at diagnosis \> 39 years old

Where it's running

• European Institute of Oncology
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Francesca Spada, MD — Istituto Europeo di Oncologia
• Study coordinator: Lorenzo Gervaso, MD
• Email: divisione.gastrointestinale@ieo.it
• Phone: +390257489258

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Somatostatin analogues after PRRT for nonfunctional neuroendocrine tumors

  This study tests whether continuing somatostatin analogues after PRRT helps patients with nonfunctional neuroendocrine tumors compared with just observation.

  Recruiting Phase 3 Washington University School of Medicine · San Francisco, California and 1 other locations · NCT07842172

• CTX-471 for NCAM-positive metastatic neuroendocrine tumors

  A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.

  Recruiting at 2 sites Phase 2 Compass Therapeutics · St Louis, Missouri and 1 other locations · NCT07684170

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

• LM-302 with tislelizumab plus chemotherapy for stomach and gastroesophageal junction cancer

  This phase 3 study tests whether LM-302 added to tislelizumab is better or safer than tislelizumab with chemotherapy in patients with newly diagnosed, unresectable or metastatic stomach/GEJ adenocarcinoma that express CLDN18.2.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 105 other locations · NCT07385703

• Relacorilant with nab-paclitaxel and gemcitabine for metastatic pancreatic adenocarcinoma

  This trial tests whether adding relacorilant to standard chemotherapy (nab-paclitaxel plus gemcitabine) helps people with previously untreated metastatic pancreatic adenocarcinoma.

  Recruiting at 19 sites Phase 2 Corcept Therapeutics · Scottsdale, Arizona and 19 other locations · NCT07259317

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.